Viking Therapeutics Inc (VKTX)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

12340 EL CAMINO REAL, SUITE 250 SAN DIEGO, CA 92130

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metaboli® to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1 first-in-human clinical trial. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

Data as of 2021-08-02 08:42:15 -0400
Market Cap480.867 Million Shares Outstanding78.19 Million Avg 30-day Volume628.527 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-0.1 Enterprise Value
Total Cash Current Debt Gross Profit
BETA1.20079 52-week High/Low10.09 / 4.95 Next Earnings Date Price to Cash FLow (P/CF) -31.6944
Data provided by IEX Cloud
View SEC Filings from VKTX instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 141 143 -1.4% 37 (2.17%) 33 (1.92%) 12.12%
13F shares: 40.933 Million 37.742 Million 8.45% 16.844 Million 15.169 Million 11.05%
% Ownership 55.2151 51.7352 6.73% 22.7219 20.7927 9.28%
New Positions: 21 21 0.0% 8 5 60.0%
Increased Positions 49 43 13.95% 12 12 0.0%
Closed Positions 20 16 25.0% 4 6 -33.33%
Reduced Positions 44 49 -10.2% 12 12 0.0%
Total Calls 1.166 Million 732.753 Thousand 59.14% 130 Thousand 239.8 Thousand -45.79%
Total Puts 290.871 Thousand 419.805 Thousand -30.71% 92.5 Thousand 91 Thousand 1.65%
PUT/CALL Ratio 0.25 0.57 -56.14% 0.71 0.38 86.84%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding VKTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding VKTX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

20 Thousand total shares from 1 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

FOEHR MATTHEW W

  • Director
66,250 2021-06-10 3

LIAN BRIAN PRESIDENT & CEO

  • Officer
  • Director
1,894,181 2021-01-19 3

MORNEAU MICHAEL VP, FINANCE AND ADMINISTRATION

  • Officer
116,062 2021-01-19 3

ZANTE GREG CHIEF FINANCIAL OFFICER

  • Officer
89,751 2021-01-19 3

MANCINI MARIANNA CHIEF OPERATING OFFICER

  • Officer
169,952 2021-01-15 3

SINGLETON J MATTHEW

  • Director
0 2021-01-04 1

MACARTNEY LAWSON

  • Director
0 2021-01-04 1

ROWLAND CHARLES A JR

  • Director
0 2021-01-04 1

ROUAN SARAH KATHRYN

  • Director
0 2021-01-04 1

LIGAND PHARMACEUTICALS INC

  • 10% Owner
No longer subject to file 2020-08-25 2

WEBSTER STEPHEN W

  • Director
0 2020-01-02 0

MASAMUNE HIROKO CHIEF DEVELOPMENT OFFICER

  • Officer
141,063 2019-01-03 0

HANLEY ROCHELLE CHIEF MEDICAL OFFICER

  • Officer
160,836 2016-05-04 0

DINERMAN MICHAEL CHIEF OPERATING OFFICER

  • Officer
694,116 2015-05-04 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

FOEHR MATTHEW W - Director

2021-06-10 16:57:28 -0400 2021-06-10 P 20,000 $5.69 a 66,250 direct 0.0 0.9868 -7.4013 10.6908 11 -7.4013 31

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
VIKING THERAPEUTICS INC VKTX 2021-08-05 22:15:04 UTC -0.3446 0.4246 2100000
VIKING THERAPEUTICS INC VKTX 2021-08-05 21:45:03 UTC -0.3425 0.4225 2100000
VIKING THERAPEUTICS INC VKTX 2021-08-05 21:15:03 UTC -0.3425 0.4225 2100000
VIKING THERAPEUTICS INC VKTX 2021-08-05 20:45:03 UTC -0.3425 0.4225 2100000
VIKING THERAPEUTICS INC VKTX 2021-08-05 20:15:04 UTC -0.3425 0.4225 2100000
VIKING THERAPEUTICS INC VKTX 2021-08-05 19:45:04 UTC -0.3425 0.4225 2100000
VIKING THERAPEUTICS INC VKTX 2021-08-05 19:15:03 UTC -0.3425 0.4225 2100000
VIKING THERAPEUTICS INC VKTX 2021-08-05 18:45:03 UTC -0.3423 0.4223 2100000
VIKING THERAPEUTICS INC VKTX 2021-08-05 18:15:03 UTC -0.3423 0.4223 2100000
VIKING THERAPEUTICS INC VKTX 2021-08-05 17:45:03 UTC -0.3423 0.4223 2100000
VIKING THERAPEUTICS INC VKTX 2021-08-05 17:15:03 UTC -0.3423 0.4223 2100000
VIKING THERAPEUTICS INC VKTX 2021-08-05 16:45:02 UTC -0.3424 0.4224 2100000
VIKING THERAPEUTICS INC VKTX 2021-08-05 16:15:03 UTC -0.3424 0.4224 2100000
VIKING THERAPEUTICS INC VKTX 2021-08-05 15:45:03 UTC -0.3424 0.4224 2100000
VIKING THERAPEUTICS INC VKTX 2021-08-05 15:15:02 UTC -0.3424 0.4224 2100000
VIKING THERAPEUTICS INC VKTX 2021-08-05 14:45:02 UTC -0.3445 0.4245 2100000
VIKING THERAPEUTICS INC VKTX 2021-08-05 14:15:04 UTC -0.3445 0.4245 2100000
VIKING THERAPEUTICS INC VKTX 2021-08-05 13:45:04 UTC -0.3445 0.4245 2100000
VIKING THERAPEUTICS INC VKTX 2021-08-05 13:15:03 UTC -0.3445 0.4245 2100000
VIKING THERAPEUTICS INC VKTX 2021-08-05 12:45:03 UTC -0.3445 0.4245 2100000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Enhanced Index Plus Fund VKTX -131.0 shares, $-613.08 2020-03-31 N-PORT
FundVantage Trust- Gotham Defensive Long Fund VKTX -21.0 shares, $-98.28 2020-03-31 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund VKTX -133.0 shares, $-622.44 2020-03-31 N-PORT
Advanced Series Trust- AST Academic Strategies Asset Allocation Portfolio VKTX -7000.0 shares, $-44275.0 2021-03-31 N-PORT
Columbia Funds Series Trust I- Multi-Manager Directional Alternative Strategies Fund VKTX -44440.0 shares, $-283971.6 2021-04-30 N-PORT
INVESTMENT MANAGERS SERIES TRUST- 361 Global Long/Short Equity Fund VKTX -353027.0 shares, $-2255842.53 2021-04-30 N-PORT
PACE SELECT ADVISORS TRUST- PACE Alternative Strategies Investments VKTX -38780.0 shares, $-247804.2 2021-04-30 N-PORT

Elevate your investments